Cholestyramine in type IIa hyperlipoproteinemia: Is low-dose treatment feasible?
作者： Bo Angelin , Kurt Einarsson
DOI: 10.1016/0021-9150(81)90101-5
关键词:
摘要: Abstract The present study was undertaken to evaluate the possible lipid-lowering effects of low-dose cholestyramine medication in type IIa hyperlipoproteinemia. A total 16 patients, 8 with heterozygous familial hypercholesterolemia and polygenic hypercholesterolemia, were investigated. After an initial 3-month period dietary treatment, patients randomly selected for 4 g twice daily, other received a dose daily 2 months. regimens then exchanged, followed further Plasma lipids lipoprotein cholesterol determined at intervals weeks. Total plasma .was reduced by 17% during treatment somewhat more (26%) daily. decrease LDL did not differ (27%) (31%); no changes triglycerides, VLDL- or HDL-cholesterol seen. Although LDL-cholesterol higher there obvious influence genetic origin on response. It is concluded that lowers, sometimes normalizes, hypercholesterolemia. Furthermore, level obtained 16-g could be predicted from response seen
elsevier.com
sci-hub.se 参考文章(21)
P. Weisweiler, G. Neureuther, P. Schwandt, The effect of cholestyramine on lipoprotein lipids in patients with primary type IIA hyperlipoproteinemia. Atherosclerosis. ,vol. 33, pp. 295- 300 ,(1979) , 10.1016/0021-9150(79)90181-3
R. Hermon Dowling, Eberhard Mack, Donald M. Small, Effects of controlled interruption of the enterohepatic circulation of bile salts by biliary diversion and by ileal resection on bile salt secretion, synthesis, and pool size in the rhesus monkey Journal of Clinical Investigation. ,vol. 49, pp. 232- 242 ,(1970) , 10.1172/JCI106232
Esko A. Nikkila, Tatu A. Miettinen, Åke Lanner, Treatment of hypercholesterolemia with Secholex A long-term clinical trial and comparison with cholestyramine Atherosclerosis. ,vol. 24, pp. 407- 419 ,(1976) , 10.1016/0021-9150(76)90133-7
G. W. Evans, G. Phillips, T. M. Mukherjee, M. R. Snow, J. R. Lawrence, D. W. Thomas, Identification of crystals deposited in brain and kidney after xylitol administration by biochemical, histochemical, and electron diffraction methods Journal of Clinical Pathology. ,vol. 26, pp. 32- 36 ,(1973) , 10.1136/JCP.26.1.32
Kurt Einarsson, Kjell Hellstrom, Mora Kallner, The Effect of Cholestyramine on the Elimination of Cholesterol as Bile Acids in Patients with Hyperlipoproteinaemia Type II and IV European Journal of Clinical Investigation. ,vol. 4, pp. 405- 410 ,(1974) , 10.1111/J.1365-2362.1974.TB00413.X
Scott M. Grundy, Treatment of Hypercholesterolemia by Interference With Bile Acid Metabolism Archives of Internal Medicine. ,vol. 130, pp. 638- 648 ,(1972) , 10.1001/ARCHINTE.1972.03650040162015
R. I. LEVY, Cholestyramine in Type II Hyperlipoproteinemia Annals of Internal Medicine. ,vol. 79, pp. 51- 58 ,(1973) , 10.7326/0003-4819-79-1-51
Kurt Einarsson, Kjell Hellström, Mora Kallner, Bile Acid Kinetics in Relation to Sex, Serum Lipids, Body Weights, and Gallbladder Disease in Patients with Various Types of Hyperlipoproteinemia Journal of Clinical Investigation. ,vol. 54, pp. 1301- 1311 ,(1974) , 10.1172/JCI107876
Scott M Grundy, Gerald Salen, E. H. Ahrens, Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. Journal of Laboratory and Clinical Medicine. ,vol. 78, pp. 94- 121 ,(1971)
Mitchell Marion, The Familial Hyperlipoproteinemias ,(1975)